131 related articles for article (PubMed ID: 10667112)
1. [The place of a new drug in the therapeutic strategy].
Castaigne A; Goehrs JM; Ravoire S
Therapie; 1999; 54(4):463-70. PubMed ID: 10667112
[TBL] [Abstract][Full Text] [Related]
2. How to anticipate the assessment of the public health benefit of new medicines?
Massol J; Puech A; Boissel JP;
Therapie; 2007; 62(5):427-35. PubMed ID: 18206104
[TBL] [Abstract][Full Text] [Related]
3. If 'atypical' neuroleptics did not exist, it wouldn't be necessary to invent them: perverse incentives in drug development, research, marketing and clinical practice.
Charlton BG
Med Hypotheses; 2005; 65(6):1005-9. PubMed ID: 16182461
[TBL] [Abstract][Full Text] [Related]
4. Unlabeled drug samples and the learned intermediary: the case for drug company liability without preemption.
Poser S
Food Drug Law J; 2007; 62(4):653-94. PubMed ID: 18557225
[No Abstract] [Full Text] [Related]
5. Turning a blind eye.
Nat Med; 2008 Jan; 14(1):1. PubMed ID: 18180702
[No Abstract] [Full Text] [Related]
6. Choice of comparator in active control trials of new drugs.
van Luijn JC; van Loenen AC; Gribnau FW; Leufkens HG
Ann Pharmacother; 2008 Nov; 42(11):1605-12. PubMed ID: 18957629
[TBL] [Abstract][Full Text] [Related]
7. [Evaluation of prescription practices and of the rational use of medicines in Niger].
Mallet HP; Njikam A; Scouflaire SM
Sante; 2001; 11(3):185-93. PubMed ID: 11641083
[TBL] [Abstract][Full Text] [Related]
8. Policy versus practice: comparison of prescribing therapy and durable medical equipment in medical and educational settings.
Sneed RC; May WL; Stencel C
Pediatrics; 2004 Nov; 114(5):e612-25. PubMed ID: 15520092
[TBL] [Abstract][Full Text] [Related]
9. The effect of pharmacotherapy audit meetings on early new drug prescribing by general practitioners.
Florentinus SR; van Hulten R; Kloth ME; Heerdink ER; Griens AM; Leufkens HG; Groenewegen PP;
Ann Pharmacother; 2007 Feb; 41(2):319-24. PubMed ID: 17244644
[TBL] [Abstract][Full Text] [Related]
10. Relative added value: what are the tools to evaluate it?
Le Jeunne C; Woronoff-Lemsi MC; David N; de Sahb R;
Therapie; 2008; 63(2):113-7, 107-11. PubMed ID: 18561884
[TBL] [Abstract][Full Text] [Related]
11. Knowledge on drug dosages of ward physicians.
Schnurrer JU; Stichtenoth DO; Frölich JC
Eur J Clin Pharmacol; 2002 Apr; 58(1):65-7. PubMed ID: 11956676
[TBL] [Abstract][Full Text] [Related]
12. Evaluating the safety and effectiveness of new drugs.
Pegler S; Underhill J
Am Fam Physician; 2010 Jul; 82(1):53-7. PubMed ID: 20590071
[TBL] [Abstract][Full Text] [Related]
13. [Access to medicines in France].
Bouvenot G; Bouvenot J
Bull Acad Natl Med; 2009 Mar; 193(3):649-59; discussion 659-62. PubMed ID: 19883016
[TBL] [Abstract][Full Text] [Related]
14. Medication errors: an analysis comparing PHICO's closed claims data and PHICO's Event Reporting Trending System (PERTS).
Benjamin DM; Pendrak RF
J Clin Pharmacol; 2003 Jul; 43(7):754-9. PubMed ID: 12856390
[TBL] [Abstract][Full Text] [Related]
15. Influences on the prescribing of new drugs.
Tobin L; de Almedia Neto AC; Wutzke S; Patterson C; Mackson J; Weekes L; Williamson M
Aust Fam Physician; 2008; 37(1-2):78-80, 83. PubMed ID: 18239759
[TBL] [Abstract][Full Text] [Related]
16. [Reassessment of drugs].
Castaigne A
Rev Prat; 2002 Mar; 52(5):507-9. PubMed ID: 11949503
[TBL] [Abstract][Full Text] [Related]
17. [Enteral nutrition: drug administration via feeding tube].
Behnken I; Gaschott T; Stein J
Z Gastroenterol; 2005 Nov; 43(11):1231-41. PubMed ID: 16267709
[TBL] [Abstract][Full Text] [Related]
18. Assessment of new cardiovascular drugs. Relationships between considerations, professional characteristics, and prescribing.
Wieringa NF; Denig P; de Graeff PA; Vos R
Int J Technol Assess Health Care; 2001; 17(4):559-70. PubMed ID: 11758299
[TBL] [Abstract][Full Text] [Related]
19. Market watch: Specialty pharmaceuticals to provide majority of sales by 2012.
Goodman M
Nat Rev Drug Discov; 2009 Mar; 8(3):184. PubMed ID: 19247297
[No Abstract] [Full Text] [Related]
20. The cost and availability of prescription drugs--what can we do in Massachusetts?
Carpenter NW; Kedikoglou S
Issue Brief (Mass Health Policy Forum); 1999 May; (4):1-41. PubMed ID: 12769091
[No Abstract] [Full Text] [Related]
[Next] [New Search]
